ArticleClinical lymphoma, myeloma & leukemia2026

Low Dose Tocilizumab for Mitigation of Cytokine Release Syndrome With T-Cell Engaging Bispecific Antibodies.

Issam S Hamadeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.